4S
1994
Scandinavian Simvastatin Survival Study
In 4,444 patients with CAD and total cholesterol 5.5–8.0 mmol/L, simvastatin reduced all-cause mortality compared with placebo.
Result
Efficacy: All-cause mortalityRR 0.7
Below 1 favours simvastatin, above 1 favours placebo.
- Absolute difference
- 3.3 points
The absolute difference is derived from the event rates.
Also reported: Major coronary events down 34 %.
- Subtopic
- Statins
- Design
- Double-blind RCT, median 5.4 yr
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Source
- Scandinavian Simvastatin Survival Study Group. Lancet. 1994;344(8934):1383-1389.doi 10.1016/S0140-6736(94)90566-5
Discussion & critique
First trial to show statin mortality reduction: ended the cholesterol-controversy era. Population enriched for high baseline cholesterol; lower-LDL questions answered later.